The Generative Brain
National Institute for Biological Standards and Control (NIBSC), MHRA, United Kingdom logo

National Institute for Biological Standards and Control (NIBSC), MHRA, United Kingdom

NIBSC is the UK public laboratory that makes and holds reference materials for biological medicines and diagnostics, does independent batch release testing, and runs applied research, on the MHRA Science Campus at South Mimms, Hertfordshire. It has been a centre of the Medicines and Healthcare products Regulatory Agency since 1 April 2013, before which it sat in the Health Protection Agency. WHO lists it first among its collaborating centres for biological standardization, and in April 2025 WHO redesignated the MHRA group, described as formerly NIBSC, for four more years. Most of that work is on vaccines and other biologicals. For prion disease its role is narrower and specific: it hosts the CJD Resource Centre, the UK bank of characterised CJD material for test development; it led the first WHO collaborative study of CJD brain reference reagents in 2004; and its staff appear on blood assay work for variant CJD, most recently a 2024 sheep blood comparison. Information only.

Key facts

  • NIBSC develops reference materials, does independent control testing for batch release and runs applied research on biological medicines and diagnostics, from the MHRA Science Campus in South Mimms.
  • It moved from the Health Protection Agency to the MHRA on 1 April 2013 and kept its services and products.
  • WHO lists NIBSC, by that name, among eight collaborating centres for biological standardization, which prepare candidate reference materials and reports for the WHO Expert Committee on Biological Standardization.
  • A 9 April 2025 government release says WHO redesignated the MHRA Science and Research group, formerly NIBSC, as a WHO Collaborating Centre for the Standardisation and Evaluation of Biologicals for four years, first designated in 1954 (the 1954 date covers the predecessor body), and that it is one of four custodian laboratories for WHO International Biological Reference Preparations. The release does not mention prions.
  • NIBSC is the operating body and registered establishment of the CJD Resource Centre, a research tissue bank set up in 2001 by the UK health department with WHO, at Blanche Lane, South Mimms.
  • The centre's reagents cover human brain and spleen homogenates from sporadic CJD, variant CJD and controls, and tissue and blood from TSE infected and control animals, for checking diagnostic and blood screening tests against common technical specifications.
  • WHO set up a working group on international reference materials for TSE diagnosis after a 1999 consultation; its first meeting was in Geneva on 21 to 22 September 1999.
  • Under that group, WHO sponsored four human brain homogenates, two sporadic CJD, one variant CJD and one normal, all methionine homozygous at codon 129, and a 2003 WHO document proposed them as reference reagents.
  • The 2004 Journal of General Virology paper led from NIBSC reports 2000 vials of each of those four homogenates and a first collaborative study, mainly of immunoblot methods, with labs including the Edinburgh surveillance unit and the Vienna prion reference centre; WHO gave the materials reference reagent status.
  • NIBSC pages list four brain preparations under the label First Reference Reagent 2003, with codes NHBX0/0001, NHBX0/0002, NHBY0/0003 and NHBZ0/0005; this was seen only as a search excerpt.
  • A 2004 NIBSC review on validating variant CJD blood tests argued that blood is the only usable sample, that a rapid infectivity assay is needed to confirm positives, and that diluted infected human brain would likely serve as routine control material.
  • In September 2008 a company release said its variant CJD blood assay had been set up in the Prion Laboratory at NIBSC for validation on fresh human blood; this is a company claim and no outcome is stated.
  • Two authors with an MHRA South Mimms address coauthored the October 2024 Blood paper comparing RT-QuIC and two PMCA assays on preclinical blood from BSE infected sheep, in which both PMCA assays reached 100 percent diagnostic sensitivity and RT-QuIC 61 percent. One of them is also the contact named on the CJD Resource Centre test evaluation page and first author of the centre's Vox Sanguinis papers.
  • Material from its CJD Resource Centre reached the 2025 INRAE E219K RT-QuIC substrate study as sporadic MM1, MV2 and variant CJD samples.
  • A Europe PMC search on the South Mimms address with prion terms in the title returns only seven papers from 2003 to 2024, which undercounts but suggests prion work is a small share of its output.

Timeline

  1. 1954First WHO designation of the group that is now NIBSC or its predecessor.
  2. 1972NIBSC begins work (search excerpt only).
  3. 1999First meeting of the WHO working group on international reference materials for TSEs, Geneva.
  4. 2001CJD Resource Centre set up at NIBSC by the UK health department with WHO.
  5. 2003WHO document proposes CJD brain homogenates as reference reagents; NIBSC labels them First Reference Reagent 2003.
  6. 2004NIBSC led collaborative study of the CJD reference reagents published in the Journal of General Virology.
  7. 2008Company variant CJD blood assay set up in the NIBSC Prion Laboratory for validation.
  8. 2009NIBSC becomes a centre of the Health Protection Agency (search excerpt only).
  9. 2013NIBSC moves from the Health Protection Agency to the MHRA.
  10. 2024Blood paper with MHRA South Mimms coauthors compares three blood assays on preclinical sheep samples.
  11. 2025WHO redesignation of the MHRA Science and Research group, formerly NIBSC, as a collaborating centre for four years announced.
Sources for this page